Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Walleye Capital LLC

Walleye Capital LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 1,502.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,083,092 shares of the biopharmaceutical company's stock after acquiring an additional 1,015,483 shares during the quarter. Walleye Capital LLC owned 0.95% of Fate Therapeutics worth $1,787,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Barclays PLC boosted its position in Fate Therapeutics by 245.3% during the third quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock valued at $1,485,000 after acquiring an additional 301,389 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Fate Therapeutics by 0.5% in the third quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company's stock valued at $7,905,000 after buying an additional 10,863 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Fate Therapeutics by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock valued at $6,431,000 after acquiring an additional 283,080 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Fate Therapeutics by 30.6% during the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 10,511 shares during the last quarter. Finally, Institute for Wealth Management LLC. bought a new stake in shares of Fate Therapeutics in the 4th quarter worth $110,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Fate Therapeutics Trading Up 1.5 %

Shares of FATE traded up $0.02 during trading hours on Thursday, reaching $1.35. 1,549,649 shares of the company's stock traded hands, compared to its average volume of 2,324,751. The firm's 50 day simple moving average is $1.04 and its 200-day simple moving average is $1.73. The stock has a market cap of $154.72 million, a PE ratio of -0.82 and a beta of 2.41. Fate Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $5.92.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.57 million. As a group, analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on FATE shares. Wells Fargo & Company dropped their price target on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC restated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. StockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, March 11th. Stifel Nicolaus dropped their target price on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Finally, Wedbush reiterated a "neutral" rating and set a $5.00 price objective on shares of Fate Therapeutics in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $5.43.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.